Lv5
1544 积分 2021-08-03 加入
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
15天前
已完结
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
25天前
已关闭
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
1个月前
已完结
Therapy with oncolytic viruses: progress and challenges
1个月前
已完结
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors
1个月前
已完结
Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)
1个月前
已完结
FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro)
1个月前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
2个月前
已完结
皖公网安备34019202002308
